PDZ and LIM domain 4 (PDLIM4), also known as RIL, is thought to be a suppressor of ovarian, breast and prostate cancers, and its low expression has been associated with hypermethylation in both primary BRCA and lymph node metastases (53–55). Here, PDLIM4 is linked to prostate carcinoma.